meRfi®-GM
NCT03589469 - LOTIS-2 - Loncastuximab tesirine & Diffuse Large B-Cell Lymphoma (DLBCL)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
A multicentre, open-label, single-arm, phase II trial evaluating Loncastuximab tesirine in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after two or more multiagent systemic treatments
Primary Outcome Measures:
Overall response rate (ORR)
The authors concluded that Loncastuximab tesirine has substantial single-agent antitumor activity and produces durable responses with an acceptable safety profile. Thus, it potentially offers a new therapeutic option for heavily pretreated patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Caimi et al. 2021 The Lancet Oncology 22: 790-800
…